⌕
Transmedics Group · TMDX · Nasdaq
Tenet 53 · Mixed
Compare
$92.21+0.91%At closeTenet 53 · Mixed
$92.21+0.83 (+0.91%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Transmedics Group (TMDX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 12, 2026 · 12:23 ET
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

● Seeking AlphaNov 11, 2026 · 09:48 ET
TransMedics: 2027 Setting Up To Be A Pivotal Year

TransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart, DENOVO Lung, CHOPS, OCS …

● Zacks Investment ResearchNov 10, 2026 · 10:31 ET
TransMedics (TMDX) Just Reclaimed the 200-Day Moving Average

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 200-day moving average, which suggests a long-term bullish tre…

● Seeking AlphaNov 10, 2026 · 05:41 ET
TransMedics: Growth Is Accelerating Again And 2027 Looks Promising

TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins, and market share gains in the recent quarter. TransMedics raised full-year revenue guidance to $764-774 million, with organic gro…

● The Motley FoolNov 9, 2026 · 19:36 ET
TransMedics: 3 Key Takeaways for Long-Term Investors

TransMedics raised 2026 revenue guidance to $764 million to $774 million. Third-quarter revenue reached $203 million, up 41% year over year.…

● Zacks Investment ResearchNov 9, 2026 · 10:35 ET
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 20-day moving average, which suggests a short-term bullish tre…

● Zacks Investment ResearchNov 9, 2026 · 10:31 ET
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average

From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 50-day moving average, and this suggests a short-term bullish tr…

● MarketBeatNov 6, 2026 · 16:16 ET
TransMedics Group Q3 Earnings Call Highlights

TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. dece…

● Schaeffers ResearchNov 6, 2026 · 11:45 ET
Unusual Options Volume Report: 3 Stocks Moving After Earnings

Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).…

● Zacks Investment ResearchNov 5, 2026 · 22:31 ET
TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Stree…

● Seeking AlphaNov 5, 2026 · 22:04 ET
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript

TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 5, 2026 · 18:20 ET
TransMedics (TMDX) Q3 Earnings and Revenues Surpass Estimates

TransMedics (TMDX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.66 per share a year ago.…

● PRNewsWireNov 5, 2026 · 16:02 ETCOMPANY'S OWN WORDS
TransMedics Reports Third Quarter 2026 Financial Results

Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts ANDOVER, Mass., Nov. 5, 2026 /PRNewswire/ -- TransMed…

● Zacks Investment ResearchNov 4, 2026 · 14:56 ET
Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.…

● Zacks Investment ResearchNov 4, 2026 · 10:16 ET
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended Septe…

● Business WireNov 1, 2026 · 16:52 ET
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $TMDX--TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law.…

● PRNewsWireOct 30, 2026 · 16:05 ETCOMPANY'S OWN WORDS
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, an…

● PRNewsWireOct 29, 2026 · 17:01 ETCOMPANY'S OWN WORDS
TransMedics to Present at Upcoming Investor Conferences

ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, an…

● GlobeNewsWireOct 27, 2026 · 07:00 ETCOMPANY'S OWN WORDS
TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet

Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraft Reliable, high-performance connectivity will support time…

● PRNewsWireOct 22, 2026 · 16:05 ETCOMPANY'S OWN WORDS
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and…

● GuruFocusOct 21, 2026 · 20:05 ET
A Look at TransMedics Group Inc (TMDX) After 3.1% Decline -- GF Value $160.75 vs Price $72.40

On October 21, 2026, TransMedics Group Inc (TMDX) shares fell by 3.1%, bringing the current price to $72.40. This decline is notable within a 52-week range of $…

● Defense WorldOct 18, 2026 · 04:32 ET
Critical Review: TransMedics Group (NASDAQ:TMDX) & iRhythm Technologies (NASDAQ:IRTC)

TransMedics Group (NASDAQ: TMDX - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses …

● GuruFocusOct 1, 2026 · 20:08 ET
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells Investors

On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5…

● PRNewsWireSep 26, 2026 · 01:44 ET
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket pay…

● Business WireSep 14, 2026 · 14:39 ETCOMPANY'S OWN WORDS
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation in…

● PRNewsWireSep 10, 2026 · 16:05 ETCOMPANY'S OWN WORDS
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just TMDX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.